Symposium:
27. Treatment of Hepatitis C
Thursday, October 27, 2016: 8:30 AM-10:00 AM
Room: 278-282

Learning Objectives:

At the conclusion of this session, participants will be able to:

  • discuss the current treatments for HCV infection
  • identify the molecular targets used to treat HCV infection
  • compare treatment in persons with cirrhosis to those without cirrhosis

Target Audience: Academicians, Clinicians, Fellows, HIV clinicians, HIV specialists, Infectious diseases physicians, Members-in-training, Pharmacists, Scientists

Tracks: HIV-STD-TB, Adult ID

Moderators:  Paul Griffiths, MD, DSc, University College London and Norah a. Terrault, MD, MPH, University of California, San Francisco

CME Credits: Maximum of 1.5 hours of AMA PRA Category 1 Credit™

ACPE Credits: ACPE 1.5 knowledge-based contact hours 0.15 of pharmacy CE

ACPE Number: 0221-9999-16-221-L01-P

Disclosures:

N. A. Terrault, Gilead: Consultant and Grant Investigator , Consulting fee and Research grant
CoCrystal Pharmaceuticals: Consultant , Consulting fee
Bristol Myers Squibb: Consultant and Grant Investigator , Consulting fee and Research grant
Biotest Pharmaceuticals: Consultant and Grant Investigator , Consulting fee and Research grant
Abbvie: Grant Investigator , Research grant
Merck: Consultant , Consulting fee
Janssen: Consultant , Consulting fee
UpToDate: Member , Royalty
CCO Hepatitis: Continuing Medical Education , Educational support
Simply Speaking Hepatitis: Continuing Medical Education , Educational support

See more of: Symposium

Findings in the abstracts are embargoed until 12:01 a.m. CDT, Wednesday Oct. 26th with the exception of research findings presented at the IDWeek press conferences.